Acumen Pharmaceuticals (ABOS) Insider Trading & Ownership $1.16 +0.04 (+3.10%) As of 07/3/2025 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Acumen Pharmaceuticals (NASDAQ:ABOS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage9.30%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$233.12K Get ABOS Insider Trade Alerts Want to know when executives and insiders are buying or selling Acumen Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ABOS Insider Buying and Selling by Quarter Acumen Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/23/2025Matt ZugaCFOSell28,902$1.72$49,711.44 1/21/2025Daniel Joseph OconnellCEOSell12,619$1.59$20,064.21 1/21/2025Eric SiemersInsiderSell3,219$1.59$5,118.21 1/21/2025Matt ZugaCFOSell4,364$1.60$6,982.40 1/21/2025Russell BartonCOOSell2,914$1.61$4,691.54 1/3/2025Daniel Joseph OconnellCEOSell47,778$1.84$87,911.52 1/3/2025Eric SiemersInsiderSell10,859$1.85$20,089.15 1/3/2025Matt ZugaCFOSell13,235$1.84$24,352.40 1/3/2025Russell BartonCOOSell7,636$1.86$14,202.96 (Data available from 1/1/2013 forward) ABOS Insider Trading Activity - Frequently Asked Questions Who is on Acumen Pharmaceuticals' Insider Roster? The list of insiders at Acumen Pharmaceuticals includes Daniel Joseph Oconnell, Derek M Meisner, Eric Siemers, Jeffrey L. Ives, Matt Zuga, Ra Capital Management, L.P., and Russell Barton. Learn more on insiders at ABOS. What percentage of Acumen Pharmaceuticals stock is owned by insiders? 9.30% of Acumen Pharmaceuticals stock is owned by insiders. Learn more on ABOS's insider holdings. Which Acumen Pharmaceuticals insiders have been buying company stock? The following insider purchased ABOS shares in the last 24 months: Ra Capital Management, L.P. ($39,999,997.50). How much insider buying is happening at Acumen Pharmaceuticals? Insiders have purchased a total of 5,161,290 ABOS shares in the last 24 months for a total of $39,999,997.50 bought. Which Acumen Pharmaceuticals insiders have been selling company stock? The following insiders have sold ABOS shares in the last 24 months: Daniel Joseph Oconnell ($160,719.73), Derek M Meisner ($31,086.84), Eric Siemers ($25,207.36), Jeffrey L. Ives ($272,249.01), Matt Zuga ($96,784.06), and Russell Barton ($29,461.59). How much insider selling is happening at Acumen Pharmaceuticals? Insiders have sold a total of 204,683 Acumen Pharmaceuticals shares in the last 24 months for a total of $615,508.59 sold. More Insider Trading Tools from MarketBeat Related Companies Rocket Pharmaceuticals Insider Ownership Aerovate Therapeutics Insider Ownership Monte Rosa Therapeutics Insider Ownership Prime Medicine Insider Ownership Olema Pharmaceuticals Insider Ownership Atea Pharmaceuticals Insider Ownership ADC Therapeutics Insider Ownership Entrada Therapeutics Insider Ownership Corvus Pharmaceuticals Insider Ownership Allogene Therapeutics Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold?3 Hot Trades for Insiders, But Are They Good Buys for Investors?Insiders Chase Income and Stability in American Tower—Here’s Why3 Tech Stocks With High and Rising Institutional Interest This page (NASDAQ:ABOS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
